SURGICAL HEMOSTATS, INTERNAL TISSUE SEALANTS, AND ADHESION BARRIERS MARKET ANALYSIS

The global surgical hemostats, internal tissue sealants, and adhesion barriers market is estimated to be valued at US$ 5,265.3 million in 2023 and is expected to exhibit a CAGR of 7.8 % during the forecast period (2023-2030).

Analysts’ Views on Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market :

Increasing prevalence of injuries and trauma cases and increasing number of surgeries related to cardiovascular diseases, neurological disorders or orthopedic surgeries can drive the growth of global surgical hemostats, internal tissue sealants, and adhesion barriers market in the forecast period. For instance, according to an article published by Eurostat, a government agency of European Union that provides statistics for European countries and regions, on July 2022,  at least 1.12 million caesarean sections were performed in the EU in 2020. Globally, a staggering 310 million major surgeries are performed each year; around 40 to 50 million in the USA and 20 million in Europe. It was estimated that 1–4% of these patients would die, up to 15% would have serious postoperative morbidity, and 5–15% would be readmitted within 30 days. Annual global mortality is around 8 million, with the leading causes of death being cardiovascular disease and stroke, cancer, and injury.

Figure 1. Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market Share (%), by Product Type, 2023

To learn more about this report, request a free sample copy

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market – Driver

Increasing prevalence of cardiovascular surgeries

The growing incidences of cardiovascular diseases are a major factor leading to the high demand for hemostats and tissue sealants. For instance, according to Heart Disease and Stroke Statistics 2022 published by the American Heart Association on February 22, 2022. In 2020, 3,658 heart transplants were performed in the United States. The highest numbers of heart transplantations were seen in California (496), Texas (302), Florida (288), and New York (250). Cardiac catheterization was the most common procedure for all years presented. An estimated 480,000 percutaneous transluminal coronary angioplasties, 371,000 inpatient bypass procedures, 1,016,000 inpatient diagnostic cardiac catheterization, 86,000 carotid endarterectomies, and 351,000 pacemaker procedures were performed for inpatients in the United States.

Introduction of products in market by key market players

The increasing launches of newer products in the market can drive the growth of the global surgical hemostats, internal tissue sealants, and adhesion barriers market. For instance, on February 23, 2022, Gunze Limited, a Japan-based medical device company, received medical device approval to manufacture and sell TENALEAF, the sheet-type absorbable adhesion barrier made in Japan. This product provides surgeons with a new option during open surgery and minimally invasive surgery, which can enable easy manipulation, and provide moderate adhesive strength for repositioning and conformable placement.

Figure 2. Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market Value (US$ Million), by Region, 2023

To learn more about this report, request a free sample copy

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global surgical hemostats, internal tissue sealants, and adhesion barriers market over the forecast period. This is due to the increasing number of Small Bowel Obstruction (SBO) cases in the U.S. In order to prevent scar or adhesion formation in SBO, the use of an adhesion barrier is necessary which can drive growth of market.  For instance, according to an article published by the Journal of Minimally Invasive Gynaecology, Small bowel obstruction is a major cause of postoperative mortality and morbidity following abdominal and pelvic surgery, with 225,000−345,000 annual admissions in the U.S. It accounts for 12–16% of emergency surgical admissions and 20% of emergency surgical procedures. Even with the advent of laparoscopic surgery, intra-abdominal adhesions remain a significant cause of SBO, accounting for 65% of cases.

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global surgical hemostats, internal tissue sealants, and adhesion barriers market. This is because of the reduced patient visits to hospitals during the COVID period. For instance, according to an article published by the International Journal of Environmental Research and Public Health on May 19, 2022, a study was performed to check the impact of the pandemic on outpatient visits for all causes in 2020. Data was extracted for 5 years, from 2016-2020. The number of all-cause outpatient visits in 2020 was 12% lower than expected.

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market Segmentation:

The global surgical hemostats, internal tissue sealants, and adhesion barriers market report is segmented into Product Type, Application, End users, and Region

Based on Product Type, the global surgical hemostats, internal tissue sealants, and adhesion barriers market is segmented into hemostat, internal tissue sealant, and adhesion barrier. Out of which, the hemostat is expected to dominate the market due to increasing hemostat product launches.

Based on Application, the global surgical hemostats, internal tissue sealants, and adhesion barriers market is segmented into surgical applications and trauma cases. The surgical application segment is expected to dominate the market over the forecast period, and this is attributed to the increasing prevalence of cardiovascular, neurological, orthopedic surgeries worldwide .

Based on End user, the global surgical hemostats, internal tissue sealants, and adhesion barriers market is segmented into hospitals, ambulatory surgical centers, and speciality clinics. The hospital segment is expected to dominate the market over the forecast period, and this is due to the increasing number of hospitals offering surgical hemostat procedures.

Among all segmentation, the product type segment has the highest potential due to the increasing research and development activities by the key market players. For instance, according to an article published by the Journal of Hand Surgery, on June 19, 2020, DendroPrime, a novel thiol-ene-based coating was evaluated to check its efficacy as an adhesion barrier between a plate and flexor tendon in in-vivo models. The application of DendroPrime onto the implanted plates demonstrated statistically significantly better mobility in the Distal interphalangeal joint (DIP) joint compared with the uncoated, bare metal plates. Furthermore, the coating prevented the growth of soft tissue around the implant, which made removal easier compared with uncoated plates. Hence, the preventive action of DendroPrime on soft tissue adhesions could reduce the need for plate removal after successful fracture healing.

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market Cross Sectional Analysis:

Increase in launches of new products in the Europe region is expected to drive the growth of the product type segment in this region. For instance, on February 26, 2020, Terumo Corporation, a Japan-based medical device company, launched a new surgical sealant Aquabrid in European Union which includes countries like France, Germany, Italy etc.  The company further planned to launch products in Eastern Europe, the Middle East, and Africa.

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market: Key Developments

On November 19, 2021, according to an article published by the Journal of Coloproctology, a study was performed at Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan to check the use of an absorbable adhesion barrier made of oxidized regenerated cellulose (INTERCEED) for temporary diverting ileostomy in minimally invasive rectal surgery. The study was performed on 36 patients who underwent ileostomy. The degree of adhesion formation between the ileal limbs and the rectus abdominis muscles, operating time, and estimated blood loss were significantly reduced in patients treated with INTERCEED compared with those treated by the conventional approach. There were no postoperative complications observed. Hence, use of INTERCEED for diverting ileostomy can contribute to reduced adhesion formation.

On October 19, 2021, Toray Industries Inc., a Japan-based manufacturer of medical devices, and ASKA Pharmaceuticals Co. Ltd., a Japan based pharmaceutical company, announced that they had signed a business collaboration agreement to develop and commercialize an adhesion barrier in Japan. Toray and ASKA jointly developed the product to obtain marketing approval of the product in Japan. According to this agreement, Toray manufactured the Product, as ASKA got exclusive market for the Product in Japan.

On September 15, 2022, RevBio Inc., U.S. based biotechnology company, received approval from the U.K.’s Regulatory Authority- Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a clinical trial for an optimized formulation of its dental bone adhesive biomaterial Tetranite. Clinical trials will be conducted on 15 patients to check the safety and efficacy of immediately stabilized dental implants following tooth extractions.

On March 25, 2020, Ethicon Inc., U.S. based healthcare company, announced the strategic regional launch of Surgical powder absorbable hemostat in Australia, New Zealand, and Thailand. It is designed to help surgeons control disruptive bleeding more efficiently. Disruptive bleeding occurs in more than 60% of open surgical procedures, which drives up health care costs and is associated with high mortality rates.

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market : Key Trends

Strategies like fundings to expand product portfolio will drive the global surgical hemostats, internal tissue sealants, and adhesion barriers market growth, For instance,  On August 31, 2021, Tissium, France based manufacturer of biodegradable sealants and adhesives for wound closure has expanded its synthetic platform to a range of indications for tissue reconstruction and treatment and for that, it has raised US$ 59 million in funding to expand into nerve, hernia repairs.

Clinical trials on newer products in field of tissue sealants and drive growth of global surgical hemostats, internal tissue sealants, and adhesion barriers market. On December 5, 2022, Salarius Pharmaceuticals, Inc., U.S. based biopharmaceutical company published preclinical data of SP-3164, an investigational small molecule protein degrader or molecular glue that showed potential for improved anti-multiple myeloma activity. It triggered the death of lab-grown cancer cells and held back cancer growth in a mouse model. Hence it may have the potential ability to treat hematological cancers.

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market : Restraint

High costs of procedures using surgical hemostats, internal tissue sealants, and adhesion barriers

The cost of treatment associated with surgical hemostats, internal tissue sealants, and adhesion barriers is very high. As it is an expensive method, this can restrain the growth of the market. According to an article published by the Journal of Vascular Surgery on June 2021, in order to prevent postoperative adhesions, patients need to undergo additional operations, which increases their medical costs and physical burden. Cost of agents aries depending on the ingredient used. Using an adhesion barrier in laparoscopic procedures increases costs by nearly US$ 162.

This restraint can be overcome by the introduction of newer government reimbursement policies that can help patients financially.

Costly research and development activities of surgical hemostats, internal tissue sealants, and adhesion barriers

The research and development activities for surgical hemostat and tissue sealant are very costly. This can affect the growth of the global surgical hemostats, internal tissue sealants, and adhesion barriers market. For instance, according to an article published by The Journal Gels on January 23, 2023, the high cost of research development are also related to high cost of the raw materials used for preparation of polymers. The time required for the R&D process is also 8-10 years which is included in the final cost. Hemostatic agents with oxidized regenerated cellulose, absorbable matrix, or microporous polysaccharide constituents are least expensive agents US$ 50-US$ 100. Agents made with microfibrillar collagen costs nearly US$ 100-US$ 300. Biologically active agents, made with virus-inactivated human fibrinogen and human thrombin are priced US$ 301-US$ 500. Dual agents containing both thrombin and absorbable gelatin, have prices between US$ 301 and US$ 500. Of all agents, synthetic adhesives were the most expensive >US$ 500.

This can be overcome introduction of newer methods to synthesize the polymers in cost-effective manner.

Global Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market - Key Players

Major players operating in the global surgical hemostats, internal tissue sealants, and adhesion barriers market include Ethicon (Johnson & Johnson), Baxter International Inc., Integra LifeSciences Holdings Corporation, Pfizer Inc., Tissuemed Ltd., Sanofi, Braun Melsungen AG, C.R. Bard, Inc., CryoLife, Inc., Cohera Medical, Inc., and CSL Behring

*Definition: Surgical hemostats, internal tissue sealants, and adhesion barriers are medical procedures/devices used to control bleeding after injuries, and during surgical procedures. Hemostats, also referred to as hemostatic clamps, arterial forceps, or pean are surgical tools used in surgical procedures to control bleeding. The hemostats were designed to clamp blood vessels of small size to manage blood flow in hemorrhagic cases. These devices are also used to grasp and secure superficial fascia during wound closure surgical procedures. The hemostats, with hinges and rings, are visibly similar to scissors.